Reported 1 day ago
Guggenheim's analyst Vamil Divan has reaffirmed a Buy rating for Pfizer Inc. (NYSE:PFE) with a price target of $33.00. This follows positive results from a Phase 3 clinical trial of Pfizer's new COVID-19 vaccine, which demonstrated significant antibody response and maintained safety standards. Despite acknowledging Pfizer's potential, the article suggests some AI stocks may offer greater investment rewards.
Source: YAHOO